Vaccination coverage and breakthrough infections of COVID-19 during the second wave among staff of selected medical institutions in India.
Journal
PLOS global public health
ISSN: 2767-3375
Titre abrégé: PLOS Glob Public Health
Pays: United States
ID NLM: 9918283779606676
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
02
2022
accepted:
24
02
2023
medline:
8
4
2023
entrez:
7
4
2023
pubmed:
8
4
2023
Statut:
epublish
Résumé
India experienced the second wave of SARS-CoV-2 infection from April 3 to June 10, 2021. During the second wave, Delta variant B.1617.2 emerged as the predominant strain, spiking cases from 12.5 million to 29.3 million (cumulative) by the end of the surge in India. Vaccines against COVID-19 are a potent tool to control and end the pandemic in addition to other control measures. India rolled out its vaccination programme on January 16, 2021, initially with two vaccines that were given emergency authorization-Covaxin (BBV152) and Covishield (ChAdOx1 nCoV- 19). Vaccination was initially started for the elderly (60+) and front-line workers and then gradually opened to different age groups. The second wave hit when vaccination was picking up pace in India. There were instances of vaccinated people (fully and partially) getting infected, and reinfections were also reported. We undertook a survey of staff (front line health care workers and supporting) of 15 medical colleges and research institutes across India to assess the vaccination coverage, incidence of breakthrough infections, and reinfections among them from June 2 to July 10, 2021. A total of 1876 staff participated, and 1484 forms were selected for analysis after removing duplicates and erroneous entries (n = 392). We found that among the respondents at the time of response, 17.6% were unvaccinated, 19.8% were partially vaccinated (received the first dose), and 62.5% were fully vaccinated (received both doses). Incidence of breakthrough infections was 8.7% among the 801 individuals (70/801) tested at least 14 days after the 2nd dose of vaccine. Eight participants reported reinfection in the overall infected group and reinfection incidence rate was 5.1%. Out of (N = 349) infected individuals 243 (69.6%) were unvaccinated and 106 (30.3%) were vaccinated. Our findings reveal the protective effect of vaccination and its role as an essential tool in the struggle against this pandemic.
Identifiants
pubmed: 37027349
doi: 10.1371/journal.pgph.0000946
pii: PGPH-D-22-00225
pmc: PMC10081792
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e0000946Informations de copyright
Copyright: © 2023 Rahi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Diabetes Metab Syndr. 2021 Nov-Dec;15(6):102327
pubmed: 34731821
Science. 2021 Dec 17;374(6574):eabl9551
pubmed: 34726481
N Engl J Med. 2021 Jun 10;384(23):2212-2218
pubmed: 33882219
BMJ. 2021 Apr 30;373:n1124
pubmed: 33931413
Lancet Infect Dis. 2022 Jan;22(1):43-55
pubmed: 34480857
NPJ Vaccines. 2021 Apr 21;6(1):60
pubmed: 33883557
Indian J Med Res. 2021 May&Jun;153(5&6):550-554
pubmed: 34341227
Blood Transfus. 2021 Jan;19(1):54-63
pubmed: 33196417
JAMA Netw Open. 2022 Jan 4;5(1):e2142210
pubmed: 34994793
Epidemiol Infect. 2021 Mar 26;149:e82
pubmed: 33766185
PLoS One. 2021 Oct 15;16(10):e0258820
pubmed: 34653228
Open Biol. 2021 Jun;11(6):200288
pubmed: 34062097
Viruses. 2021 Sep 07;13(9):
pubmed: 34578363
Front Cell Infect Microbiol. 2021 Nov 02;11:767771
pubmed: 34796130
PLoS One. 2021 Mar 31;16(3):e0248029
pubmed: 33788866
Cureus. 2021 Oct 27;13(10):e19070
pubmed: 34824945
PLOS Glob Public Health. 2021 Dec 15;1(12):e0000083
pubmed: 36962105
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
Diabetes Metab Syndr. 2021 May-Jun;15(3):1007-1008
pubmed: 33991805
Transfus Med Hemother. 2021 May;48(3):161-167
pubmed: 34177420
Vaccines (Basel). 2021 Dec 31;10(1):
pubmed: 35062715